Natco Pharma- Kothur facility gets 9 observations from USFDA

NEW DELHI: Natco Pharma Thursday said the US health regulator has made nine observations after the completion of inspection of its Kothur formulation facility in Telangana.

Read Also: Swiss company Actelion moves US court against Natco Pharma over generic of its patented drug

"At the end of the inspection, the facility received 9 observations, with no repeat observations and mostly procedural in nature," Natco Pharma said in a BSE filing.

The company believes that none of the observations are related to data integrity and that they can be addressed within a short period of time, it added.

Natco Pharma said it will provide due justifications and corrective action plan within next 15 working days to address the USFDA observations.

Read Also: Natco Pharma files ANDA for generic version of Bosentan tablets for oral suspension

Shares of Natco Pharma were trading 0.67 per cent lower at Rs 543.30 apiece on BSE.